Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

被引：0
|
作者：
Mehmet Akce
Anthony El-Khoueiry
Sarina A. Piha-Paul
Emeline Bacque
Peng Pan
Zhi-Yi Zhang
Reginald Ewesuedo
Divya Gupta
Yongqiang Tang
Ashley Milton
Stefan Zajic
Patricia L. Judson
Cindy L. O’Bryant
机构：
[1] Winship Cancer Institute of Emory University,
[2] University of Southern California Norris Comprehensive Cancer Center,undefined
[3] University of Texas MD Anderson Cancer Center,undefined
[4] GlaxoSmithKline,undefined
[5] EQRx,undefined
[6] Dyne Therapeutics,undefined
[7] Mersana Therapeutics,undefined
[8] GlaxoSmithKline,undefined
[9] University of Colorado Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 88卷
关键词：
Niraparib; Pharmacokinetics; Safety; Dosing; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：825 / 836
页数：11
相关论文
共 50 条
  • [41] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Michael A. Tortorici
    Melvin Toh
    S. V. Rahavendran
    Robert R. LaBadie
    Christine W. Alvey
    Thomas Marbury
    Ernesto Fuentes
    Matthew Green
    Grace Ni
    Brian Hee
    Yazdi K. Pithavala
    [J]. Investigational New Drugs, 2011, 29 : 1370 - 1380
  • [42] Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment
    Abou-Alfa, Ghassan K.
    Lewis, Lionel D.
    LoRusso, Patricia
    Maitland, Michael
    Chandra, Priya
    Cheeti, Sravanthi
    Colburn, Dawn
    Williams, Sarah
    Simmons, Brian
    Graham, Richard A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (01) : 29 - 36
  • [43] Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
    Grechko, Nikolay
    Skarbova, Viera
    Tomaszewska-Kiecana, Monika
    Ramlau, Rodryg
    Centkowski, Piotr
    Drew, Yvette
    Dziadziuszko, Rafal
    Zemanova, Milada
    Beltman, Jeri
    Nash, Eileen
    Habeck, Jenn
    Liao, Mingxiang
    Xiao, Jim
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (02) : 259 - 270
  • [44] Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
    Nikolay Grechko
    Viera Skarbova
    Monika Tomaszewska-Kiecana
    Rodryg Ramlau
    Piotr Centkowski
    Yvette Drew
    Rafal Dziadziuszko
    Milada Zemanova
    Jeri Beltman
    Eileen Nash
    Jenn Habeck
    Mingxiang Liao
    Jim Xiao
    [J]. Cancer Chemotherapy and Pharmacology, 2021, 88 : 259 - 270
  • [45] Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer
    Anthony B. El-Khoueiry
    John Sarantopoulos
    Cindy L. O’Bryant
    Kristen K. Ciombor
    Huiping Xu
    Melissa O’Gorman
    Jayeta Chakrabarti
    Tiziana Usari
    Bassel F. El-Rayes
    [J]. Cancer Chemotherapy and Pharmacology, 2018, 81 : 659 - 670
  • [46] Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer
    El-Khoueiry, Anthony B.
    Sarantopoulos, John
    O'Bryant, Cindy L.
    Ciombor, Kristen K.
    Xu, Huiping
    O'Gorman, Melissa
    Chakrabarti, Jayeta
    Usari, Tiziana
    El-Rayes, Bassel F.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 659 - 670
  • [47] Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment
    Ghassan K. Abou-Alfa
    Lionel D. Lewis
    Patricia LoRusso
    Michael Maitland
    Priya Chandra
    Sravanthi Cheeti
    Dawn Colburn
    Sarah Williams
    Brian Simmons
    Richard A. Graham
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 80 : 29 - 36
  • [48] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Kurata, Akifumi
    Yoshida, Takafumi
    Inoue, Megumi
    Ishizuka, Tomoko
    Nakatsu, Takafumi
    Shimizu, Takako
    Kato, Manabu
    Nishikawa, Yasuhiro
    Ishizuka, Hitoshi
    [J]. ADVANCES IN THERAPY, 2020, 37 (01) : 253 - 264
  • [49] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Akifumi Kurata
    Takafumi Yoshida
    Megumi Inoue
    Tomoko Ishizuka
    Takafumi Nakatsu
    Takako Shimizu
    Manabu Kato
    Yasuhiro Nishikawa
    Hitoshi Ishizuka
    [J]. Advances in Therapy, 2020, 37 : 253 - 264
  • [50] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    John Marcinak
    Majid Vakilynejad
    Akifumi Kogame
    Yoshihiko Tagawa
    [J]. Drugs in R&D, 2018, 18 : 109 - 118
12345